Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avecho BiotechnologyASX:AVE Return-on-Tangible-Asset is -48.71% as of Dec. 2025. The stock has 2 warning signs investors should review. Among 1,416 Biotechnology companies, Avecho Biotechnology ranks worse than 69.99% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Avecho Biotechnology's annualizedNet Income for the quarter that ended in Dec. 2025 was A$-3.48 Mil. Avecho Biotechnology's average total tangible assets for the quarter that ended in Dec. 2025 was A$7.15 Mil. Therefore, Avecho Biotechnology's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2025 was -48.71%.
The historical rank and industry rank for Avecho Biotechnology's Return-on-Tangible-Asset or its related term are showing as below:
ASX:AVE'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -119.23 Med: -71.44 Max: 28.06
Current: -68.68
During the past 13 years, Avecho Biotechnology's highest Return-on-Tangible-Asset was 28.06%. The lowest was -119.23%. And the median was -71.44%.
ASX:AVE's Return-on-Tangible-Asset is ranked worse than 69.99% of 1416
companies
in the Biotechnology industry
Industry Median: -35.76
vs ASX:AVE: -68.68
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Avecho Biotechnology Return-on-Tangible-Asset Related Terms
Avecho Biotechnology Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Avecho Biotechnology's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AVE vs VRTX, REGN, ALNY: Return-on-Tangible-Asset Comparison
For the Biotechnology subindustry, Avecho Biotechnology's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avecho Biotechnology Return-on-Tangible-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avecho Biotechnology's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Avecho Biotechnology's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Dec. 2025) net income data.
What does a Return-on-Tangible-Asset of -48.71% mean?
Avecho Biotechnology (ASX:AVE) has a Return-on-Tangible-Asset of -48.71% as of Dec. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Avecho Biotechnology and its competitors. According to the industry distribution chart, Avecho Biotechnology ranks #991 out of 1416 companies in the Biotechnology industry, placing it in the top 70%.
Is Avecho Biotechnology's Return-on-Tangible-Asset too high?
Avecho Biotechnology's current Return-on-Tangible-Asset is -48.71%. Based on the distribution chart, Avecho Biotechnology ranks #991 out of 1416 companies in the Biotechnology industry, which is below the industry midpoint.
How does Avecho Biotechnology's Return-on-Tangible-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avecho Biotechnology ranks #991 out of 1416 companies for Return-on-Tangible-Asset. This places Avecho Biotechnology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Biotechnology company?
A good Return-on-Tangible-Asset depends on the Biotechnology industry context. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Avecho Biotechnology and its competitors. Avecho Biotechnology's current Return-on-Tangible-Asset is -48.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avecho Biotechnology stock overvalued right now?
Avecho Biotechnology (ASX:AVE) has a current Return-on-Tangible-Asset of -48.71%. The current Return-on-Tangible-Asset is -48.71%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Avecho Biotechnology (ASX:AVE), the current Return-on-Tangible-Asset is -48.71% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology Tocopheryl Phosphate Mixture (TPM), for the pharmaceutical, skincare, and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches, including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AVE has been successfully added to your 
